Extended adjuvant endocrine treatment for premenopausal women: A Delphi approach to guide clinical practice

The use of an aromatase inhibitor (AI) in combination with ovarian function suppression (OFS) has become the mainstay of adjuvant endocrine therapy in high-risk premenopausal patients with hormone receptor-positive breast cancer. Although five years of such therapy effectively reduces recurrence rat...

Descripción completa

Detalles Bibliográficos
Autores principales: Buono, Giuseppe, Arpino, Grazia, Del Mastro, Lucia, Fabi, Alessandra, Generali, Daniele, Puglisi, Fabio, Zambelli, Alberto, Cinieri, Saverio, Nuzzo, Francesco, Di Lauro, Vincenzo, Vigneri, Paolo, Bianchini, Giampaolo, Montemurro, Filippo, Gennari, Alessandra, De Laurentiis, Michelino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9645191/
https://www.ncbi.nlm.nih.gov/pubmed/36387212
http://dx.doi.org/10.3389/fonc.2022.1032166

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9645191/
https://www.ncbi.nlm.nih.gov/pubmed/36387212
http://dx.doi.org/10.3389/fonc.2022.1032166

Ejemplares similares